- Due to insufficient company valuation data, it is not possible to provide a rating.
2. The current stock trend is in a consolidation phasewith strongest momentum accumulation in the intermediate-term.
3. The current potential for an upward price swing is lower, awaiting a swing trading score of 4 or above.
4. No dividend history, not ideal for dividend-oriented buy-and-hold strategy.
Health Care | Pharmaceuticals and Biotechnology
GENE 5 Dimension Analysis
Analysis Instruction of GENE
Performance
| 1D | 1M | 3M | 6M | 1Y | |
| GENE | 0.97% | -8.88% | -7.32% | -33.62% | -34.07% |
| Avg of Sector | -0.33% | -7.78% | -12.89% | -9.97% | -14.44% |
| S&P 500 | 0.01% | -5.04% | -3.64% | 4.36% | 19.60% |